RecruitingNCT07039552
Rare condition
Hereditary breast and/or ovarian cancer syndrome
1
studies recruiting now
as of 7 Sept 2026
37
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
26 Jun 2025
most recent study posted
among recruiting studies
Recruiting trials
Showing the 1 most recently updated recruiting study, as recorded 7 Sept 2026. Live status on each study page.
Search all Hereditary breast and/or ovarian cancer syndrome studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Hereditary breast and/or ovarian cancer syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Hereditary breast and/or ovarian cancer syndrome
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (PTEN, RAD51, BRCA2, BRIP1, CHEK2, TP53).
Treatments being studied
11 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Letrozole (Femara)
Phase 2Tamoxifen Citrate (Emblon)
Phase 2Rucaparib
Phase 2Trabectedin (Yondelis)
Phase 2Arzoxifene Hydrochloride
Phase 2Docetaxel (Beizray)
Phase 2Carboplatin (Carboplatin)
Phase 1Talazoparib
+ 3 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).